Lacrifill® Canalicular Gel is a new and innovative CE-marked and FDA-cleared medical device for lacrimal occlusion.
It is a transparent and sterile gel made of cross-linked hyaluronic acid, intended to block tear drainage by occlusion of the canalicular system.
Lacrifill® is indicated for use, for up to 6 months, in patients experiencing dry eye symptoms, and comes in a prefilled syringe that is sufficient for administration in both eyes of one patient.
There was comparable incidence of of ocular device-related AEs between treatment groups in the pivotal clinical trial
Scroll to the right to see all data
| Parameter | Lacrifill® (n=103) n (%) |
Form Fit (n=54) n (%) |
Total (N=157) n (%) |
|---|---|---|---|
| Number of patients with ≥1 ocular device-related AE | 26 (25.2) | 14 (25.9) | 40 (25.5) |
| Most common ocular device-related AEs | |||
| Eyelid pain | 5 (4.9) | 1 (1.9) | 6 (3.8) |
| Epiphora | 8 (7.8) | 3 (5.6) | 11 (7.0) |
| Blepharitis | 2 (1.9) | 1 (1.9) | 3 (1.9) |
| Procedural pain | 7 (6.8) | 3 (5.6) | 10 (6.4) |
N=total number of patients in the respective treatment group. Percentages were based on the total number of patients in each treatment group. AEs were coded using Medical Dictionary for Regulatory Activities (MedDRA) 23.1. Patients experiencing >1 AE were counted once within that preferred term. Device-related AEs were those categorised as definite, probable, and possible.
Adapted from: Packer M, et al. 2024.¹
Lacrifill is contraindicated for the following patients1
- With lacrimal outflow obstruction
- With inflammation of the ocular surface not associated with dry eye
- With active ocular or periocular infection
- Allergic to hyaluronic acid
Qualitative and quantitive components of Lacrifill Canalicular Gel1
| Ingredients | Content per g |
|---|---|
| Crosslinked sodium hyaluronate | 20 mg |
| Sodium chloride | 9 mg |
| Potassium dihydrogen phosphate, KH₂PO₄ | 0.02 mg |
| Disodium hydrogen phosphate dihydrate, Na₂HPO₄ · 2H₂O | 0.22 mg |
| Water for Injection (WFI) | ad 1g |

